Fresenius Medical Care (NYSE:FMS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note issued to investors on Friday. The brokerage issued a strong-buy rating on the stock.

Several other research firms have also recently issued reports on FMS. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price target on the stock. Finally, Truist Financial upped their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Fresenius Medical Care has a consensus rating of “Hold” and a consensus target price of $24.30.

Fresenius Medical Care Price Performance

Shares of Fresenius Medical Care stock opened at $22.38 on Friday. The company’s fifty day simple moving average is $22.21 and its two-hundred day simple moving average is $20.64. Fresenius Medical Care has a 12-month low of $17.93 and a 12-month high of $24.31. The firm has a market cap of $13.13 billion, a PE ratio of 18.50, a price-to-earnings-growth ratio of 0.96 and a beta of 0.93. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42.

Institutional Investors Weigh In On Fresenius Medical Care

Several hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in shares of Fresenius Medical Care by 43.3% during the fourth quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock valued at $162,000 after acquiring an additional 2,166 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Fresenius Medical Care by 18.2% during the third quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company’s stock valued at $211,000 after buying an additional 1,528 shares during the last quarter. Franklin Resources Inc. raised its holdings in Fresenius Medical Care by 3.3% in the 3rd quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock worth $1,490,000 after purchasing an additional 2,386 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Fresenius Medical Care in the third quarter worth about $38,000. Finally, MML Investors Services LLC raised its stake in Fresenius Medical Care by 5.3% during the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock worth $320,000 after acquiring an additional 753 shares during the period. 8.37% of the stock is currently owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.